Biodesix Announces Using the services of of Ryan Siurek as Chief Accounting Officer

Biodesix Announces Hiring of Ryan Siurek as Main Accounting Officer

Biodesix, Inc. (Nasdaq: BDSX), a foremost information-driven diagnostic options firm with a aim in lung ailment, right now introduced that Ryan Siurek has joined the company as Main Accounting Officer reporting to Ms. Robin Harper Cowie, Main Economical Officer.

“I am quite delighted to welcome Ryan as our new Main Accounting Officer. His substantial finance and accounting leadership experience will support Biodesix increase as we enter our future stage of development in 2021 and over and above,” mentioned Ms. Cowie.

Prior to signing up for the Organization, Mr. Siurek served as Senior Vice President, Chief Accounting Officer and Controller of Vail Resorts, Inc. from April 2016 to September 2020. From January 2009 to April 2016, Mr. Siurek served as an executive at Sprint Company wherever he held a variety of accounting and finance roles such as Vice President Controller & Chief Accounting Officer and Vice President, Divisional Chief Fiscal Officer for the prepaid and wholesale and enterprise alternatives divisions. Mr. Siurek attained a BBA & MS in Accounting from Texas A&M University, and is a Qualified General public Accountant. Mr. Siurek also serves as a member of the American Institute of Qualified General public Accountants (AICPA) Financial Reporting Government Committee (FinREC), a senior committee focused on economical reporting.

About Biodesix

Biodesix is a top diagnostic organization with a concentration in lung illness. The Company develops diagnostic exams addressing critical clinical questions by combining multi-omics by means of the electrical power of synthetic intelligence. Biodesix is the to start with enterprise to give 6 non-invasive tests for sufferers with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ exam and the Platelia SARS-CoV-2 Complete Ab in reaction to the world-wide pandemic and virus that impacts the lung and triggers COVID-19. The blood-based Biodesix Lung Reflex® system for lung most cancers patients integrates the GeneStrat® and VeriStrat® exams to guidance treatment conclusions with success in 72 several hours, expediting time to treatment. The blood-based mostly Nodify Lung™ nodule hazard assessment tests system, consisting of the Nodify XL2® and the Nodify CDT™ exams, evaluates the risk of malignancy in incidental pulmonary nodules, enabling doctors to far better triage clients to the most ideal class of action. Biodesix also collaborates with numerous of the world’s main biotechnology and pharmaceutical organizations to fix intricate diagnostic issues in lung condition. For extra information about Biodesix, visit biodesix.com.

Observe Regarding Ahead-Looking Statements

This push launch may well include forward-wanting statements that contain substantial hazards and uncertainties for needs of the secure harbor offered by the Non-public Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historic truth, are forward-on the lookout statements. The text “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are supposed to determine ahead-wanting statements. These statements are based mostly on management’s present expectations and require risks and uncertainties. True final results and effectiveness could differ materially from those people projected in the forward-looking statements as a result of many things. Biodesix has based mostly these ahead-hunting statements mainly on its recent anticipations and projections about foreseeable future gatherings and traits. These forward-looking statements are issue to a selection of challenges, uncertainties and assumptions. Furthermore, Biodesix operates in a aggressive and quickly transforming surroundings. New challenges emerge from time to time. It is not probable for its administration to forecast all threats, nor can it assess the effect of all variables on its business or the extent to which any component, or mixture of aspects, may trigger precise results to differ materially from people contained in any ahead-looking statements it may make. Biodesix undertakes no obligation to revise or publicly release the benefits of any revision to these types of forward-looking statements, other than as essential by legislation. Specified these threats and uncertainties, readers are cautioned not to location undue reliance on this kind of ahead-searching statements. All forward-searching statements are skilled in their entirety by this cautionary statement.